Precipio Inc Total Liabilities

Latest as of September 2025: $7.40 Million USD

Precipio Inc total liabilities. Based on the latest financial reports, Precipio Inc (PRPO) has total liabilities worth $7.40 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PRPO financial resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Precipio Inc (1999–2024)

Total liabilities of Precipio Inc from 1999 to 2024. This chart illustrates how Precipio Inc's total liabilities have evolved over time, based on quarterly financial data.

Precipio Inc Competitors by Total Liabilities

The table below lists competitors of Precipio Inc ranked by their total liabilities.

Company Country Total Liabilities
Sakuma Exports Limited
NSE:SAKUMA
India Rs1.92 Billion
Candles Scandinavia AB Series B
ST:CANDLE-B
Sweden Skr199.15 Million
Jiangsu Wuzhong Industrial Co Ltd
SHG:600200
China CN¥1.93 Billion
Katana Capital Ltd
AU:KAT
Australia AU$4.82 Million
Urban One Inc Class D
NASDAQ:UONEK
USA $642.06 Million
Wijaya Karya Beton
JK:WTON
Indonesia Rp2.79 Trillion
Microvision Inc
NASDAQ:MVIS
USA $67.99 Million
WebCash Corporation
KQ:053580
Korea ₩20.23 Billion

Liability Composition Analysis (1999–2024)

This chart breaks down Precipio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Precipio Inc (PRPO) total assets.

Liquidity & Leverage Metrics

Precipio Inc Total Liabilities Ratios Explained

Precipio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.27 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.54 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.35 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Precipio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Precipio Inc (1999–2024)

The table below shows the annual total liabilities of Precipio Inc from 1999 to 2024.

Year Total Liabilities Change
2024-12-31 $4.90 Million +33.50%
2023-12-31 $3.67 Million -28.52%
2022-12-31 $5.14 Million -11.96%
2021-12-31 $5.83 Million -10.93%
2020-12-31 $6.55 Million +3.89%
2019-12-31 $6.31 Million -59.27%
2018-12-31 $15.48 Million +8.76%
2017-12-31 $14.23 Million -30.93%
2016-12-31 $20.61 Million +16.86%
2015-12-31 $17.64 Million -24.80%
2014-12-31 $23.45 Million +24.54%
2013-12-31 $18.83 Million +1.70%
2012-12-31 $18.52 Million -17.75%
2011-12-31 $22.51 Million -4.31%
2010-12-31 $23.53 Million +441.85%
2009-12-31 $4.34 Million -0.21%
2008-12-31 $4.35 Million -12.77%
2007-12-31 $4.99 Million -6.40%
2006-12-31 $5.33 Million -28.32%
2005-12-31 $7.43 Million -64.47%
2004-12-31 $20.92 Million +70.83%
2003-12-31 $12.25 Million -2.18%
2002-12-31 $12.52 Million +74.34%
2001-12-31 $7.18 Million +84.30%
2000-12-31 $3.90 Million -82.34%
1999-12-31 $22.06 Million --

About Precipio Inc

NASDAQ:PRPO USA Diagnostics & Research
Market Cap
$30.16 Million
Market Cap Rank
#23552 Global
#5128 in USA
Share Price
$18.62
Change (1 day)
+4.67%
52-Week Range
$17.79 - $32.37
All Time High
$12238.78
About

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomar… Read more